Page last updated: 2024-11-08

1-(4-bromophenyl)-2-phenylethan-1-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID519738
CHEBI ID190542
SCHEMBL ID1351697

Synonyms (43)

Synonym
4-bromodesoxybenzoin
benzyl 4-bromophenyl ketone
AH-034/01393018
1-(4-bromophenyl)-2-phenylethanone ,
benzyl 4-bromophenyl ketone, 97%
MAYBRIDGE4_003239
NCGC00176058-01
HMS1530D05
2001-29-8
b2020 ,
BRD-K64462698-001-01-5
STL011094
1-(4-bromophenyl)-2-phenylethan-1-one
CHEBI:190542
4'-bromo-2-phenylacetophenone
benzylbromanuidyl(phenyl)methanone
A814165
AKOS005202967
ethanone,1-(4-bromophenyl)-2-phenyl-
FT-0622765
AB01330624-02
BBL027816
4--bromodeoxybenzoin
4-bromodeoxybenzoin
1-(4-bromo-phenyl)-2-phenyl-ethanone
2-phenyl-p-bromoacetophenone
SCHEMBL1351697
ethanone, 1-(4-bromophenyl)-2-phenyl-
AC-30019
1-(4-bromophenyl)-2-phenylethanone #
mfcd00016331
DTXSID10334126
J-012941
NCGC00176058-02
DS-6553
benzyl 4-brornophenyl ketone
D70861
4 inverted exclamation mark -bromo-2-phenylacetophenone
SY049175
AB90876
CS-0156335
?4'-bromo-2-phenylacetophenone
phenyl-(phenylmethyl)bromanuidylmethanone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.13 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]